Induction of cell cycle arrest and apoptosis in human cervix carcinoma cells during therapy by cisplatin

Cancer Detection and Prevention

Volumn 27, Issue 6, 2003, Pages 481-493

  Schloffer, Daniela ^a   Horky, Marcel ^b   Kotala, Vladimir ^b   Wȩsierska Ga̧dek, Józefa ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Activated caspases; Cytochrome C release; DNA replication; Mitosis; Nucleolar segregation; PARP 1 degradation; Phosphorylation of Rb

Indexed keywords

EID: 0345166829     PISSN: 0361090X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cdp.2003.07.002     Document Type: Article

References (33)

1. Cohen SM, Lippard SJ. Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucl Acid Res Mol Biol 2001;67:93-130.
2. Fichtinger-Schepman AM, van der Veer JL, den Hartog JH, et al. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification and quantitation. Biochemistry 1985;24:707-13.
3. Huang JC, Zamble DB, Reardon JT, et al. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci USA 1994;91:10394-8.
4. Fichtinger-Schepman AM, Dijt FJ, Bedford P, et al. Induction and removal of cisplatin-DNA adducts in human cells in vivo and in vitro as measured by immunochemical techniques. IARC Sci Publ 1988;89:321-8.
5. Zamble DB, Mu D, Reardon JT, et al. Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 1996;35:10004-13.
6. Ormerod MG, Orr RM, Peacock JH. The role of apoptosis in cell killing by cisplatin: a flow cytometric study. Br J Cancer 1994;69:93-100.
7. Ormerod MG, O'Neill CF, Robertson D, et al. Cisplatin induces apoptosis in a human ovarian carcinoma cell line without concomitant internucleosomal degradation of DNA. Exp Cell Res 1994;211:231-7.
8. Sorenson CM, Eastman A. Mechanism of cis-diamminedichloroplatinum(II)- induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res 1988;48:4484-8.
9. Sorenson CM, Barry MA, Eastman A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 1990;82:749-55.
10. Tamm I, Schriever F, Dorken B. Apoptosis: implications of basic research for clinical oncology. Lancet Oncol 2001;2:33-42.
11. Olson M, Kornbluth S. Mitochondria in apoptosis and human disease. Curr Mol Med 2001;1:91-122.
12. Zou H, Henzel WJ, Liu X, et al. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome C-dependent activation of caspase-3. Cell 1997;90:405-13.
13. Saleh A, Srinivasula SM, Acharya S, et al. Cytochrome C and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation. J Biol Chem 1999;274:17941-5.
14. Horky M, Wurzer G, Kotala V, et al. Segregation of nucleolar components coincides with caspase-3 activation in cisplatin-treated HeLa cells. J Cell Sci 2001;114:663-70.
15. Wesierska-Gadek J, Schloffer D, Kotala V, Horky M. Escape of p53 protein from E-6 mediated degradation in HeLa cells after cisplatin therapy. Int J Cancer 2002;101:128-36.
16. Wesierska-Gadek J, Wang Z-Q, Schmid G. Reduced stability of regularly spliced but not alternatively spliced p53 protein in PARP-deficient mouse fibroblasts. Cancer Res 1999;59:28-34.
17. Smith FG, Murray PG, Crocker J. Correlation between PCNA and AgNOR scores in non-Hodgkin's lymphomas using sequential staining technique. J Clin Pathol 1993;46:28-31.
18. Wesierska-Gadek J, Bohrn E, Herceg Z, et al. Differential susceptibility of normal and PARP kock-out mouse fibroblasts to proteasome inhibitors. J Cell Biochem 2000;78:681-96.
19. Vindelov LL, Christensen IJ, Nissen NI. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983;3:323-7.
20. Wesierska-Gadek J, Penner E, Hitchman E, et al. Nucleolar proteins B23 and C23 as target antigens in chronic graft-versus-host disease. Blood 1992;79:1081-6.
21. Leitinger N, Wesierska-Gadek J. ADP-ribosylation of nucleolar proteins in HeLa tumor cells. J Cell Biochem 1993;52:153-8.
22. Fiskum G, Craig SW, Decker GL, et al. The cytoskeleton of digitonin-treated rat hepatocytes. Proc Natl Acad Sci USA 1980;77:3430-4.
23. Fiskum G, Kowaltowksi AJ, Andreyev AY, et al. Apoptosis-related activities measured with isolated mitochondria and digitonin-permeabilized cells. Meth Enzymol 2000;322:222-34.
24. Smetana K, Likovsky Z. Studies on nucleoli of maturing frog erythroblasts. Z Zellforsch Mikrosk Anat 1972;133:367-75.
25. Yung BY, Bor AM, Chan PK. Short exposure to actinomycin D induces "reversible" translocation of protein B23 as well as "reversible" inhibition of cell growth and RNA synthesis in HeLa cells. Cancer Res 1990;50:5987-91.
26. Mowat MR. p53 in tumor progression: life, death, and everything. Adv Cancer Res 1998;74:25-48.
27. Blagosklonny MV. p53: an ubiquitous target of anticancer drugs. Int J Cancer 2002;98:161-6.
28. Maldonado V, Melendez-Zajgla J, Ortega A. Modulation of NF-κB, p53 and Bcl-2 in apoptosis induced by cisplatin in HeLa cells. Mutat Res 1997;381:67-75.
29. Melendez-Zajgla J, Cruz E, Maldonado V, et al. Mitochondrial changes during the apoptotic process of HeLa cells exposed to cisplatin. Biochem Mol Biol Int 1999;47:765-71.
30. Hahn C, Hirsch B, Jahnke D, et al. Three new types of Apaf-1 in mammalian cells. Biochem Biophys Res Commun 1999;261:746-9.
31. Heck DV, Yee CL, Howley PM, et al. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci USA 1992;89:4442-6.
32. Slebos RJ, Lee MH, Plunkett BS, et al. p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc Natl Acad Sci USA 1994;91:5320-4.
33. Karin M, Lin A. NF-κB at the crossroads of life and death. Nat Immunol 2002;3:221-7.